Paul Thurk is a Managing Director with ARCH Venture Partners.
Mr. Thurk joined ARCH in 2000 from SSM Ventures, via a two-year Kauffman Fellowship with the Partnership. He recently established ARCH’s Dublin, Ireland office to assess European-sourced technology and investment opportunities.
Mr. Thurk was co-founder and initial CEO of Innovalight (acquired by DuPont-DD) and CoolEdge Lighting. He has participated in the development of ARCH portfolio companies Kotura (acquired by Mellanox), Nitronex (acquired by MACOM), Arivale, Sana Biotechology, Luna DNA, Nebula Genomics, BioPalette Japan, Cambrios, and Semprius. He co-founded Carrick Therapeutics and Genomics Medicine Ireland, and serves as a Director of both companies, and is a board observer to Movidius in Dublin. He is co-founder and current CEO of Pretzel Therapeutics. He also assisted in the organization of Sana by bringing in initial IP originating from a transatlantic academic partnership.
Mr. Thurk began at ARCH focusing on solid-state lighting, semiconductors, advanced materials, nanotechnology, electronics and optoelectronics. Mr. Thurk has also been a key part of ARCH’s efforts at Los Alamos National Laboratory and at Sandia National Laboratories in their entrepreneur-in-residence program with the U.S. Department of Energy.
Formerly, Mr. Thurk was a Director of Operations for NABS, a supplier of electronics components where he established operations on behalf of NABS in five countries and was responsible for setting-up business infrastructure, systems, personnel, and processes in each. In addition, he developed and launched several innovative supply chain management programs.
Mr. Thurk holds a B.S. in Economics from the Wharton School of the University of Pennsylvania and an M.B.A. from the University of Texas at Austin.